Aduro Biotech to Host and Webcast an Investor Event in Conjunction with the 2017 ASCO Annual Meeting

BERKELEY, Calif., May 26, 2017 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that the Aduro management team will host an investor event with special guest speaker Jason J. Luke, M.D., FACP, Assistant Professor of Medicine at the University of Chicago and a principal investigator for the Phase 1 dose-escalation trial of ADU-S100 in patients with advanced/metastatic solid tumors or lymphomas. This event will take place in conjunction with the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on Saturday June 3, 2017, at 6:00 a.m. Central Time.

Dr. Luke is a clinical investigator and a medical oncologist whose research focuses on translational therapeutic advances for melanoma and early phase drug development, particularly immunotherapy.

To access the live webcast and subsequent archived recording of this and other company presentations, please visit the investor section of Aduro’s website at

About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro’s technology platforms, which are designed to harness the body’s natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro’s LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, lung and prostate cancers. Additionally, a personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor. Aduro’s STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit

CONTACT: Contact:
Sylvia Wheeler
SVP, Corporate Affairs
510 809 9264

Media Contact:
Susan Lehner
510 809 2137